Over 23,000 consented patients are in Omico's cancer databases; Fortrea aims to link patients to trials.
Fortrea and Omico have announced a collaboration to accelerate precision oncology research in Australia by connecting cancer patients with biomarker-matched clinical trials. Omico's extensive clinic-genomic databases, containing over 23,000 consented patients and referrals from more than 1,600 clinicians, will be leveraged to provide patient population insights and trial-matching capabilities. This partnership aims to improve study planning, site selection, and recruitment, thereby expanding access to biomarker-driven research for cancer patients.
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Fortrea and Omico have announced a collaboration to accelerate precision oncology research, aiming to connect cancer patients with biomarker-matched clinical trials, particularly in Australia. This partnership combines Fortrea's oncology clinical trial expertise with Omico's Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program, which is Australia's largest cancer genomics initiative. The goal is to improve trial planning, site selection, and patient recruitment, ultimately expanding access to advanced oncology research globally.
Fortrea Holdings Jumps 5.9% Amid Sector-Wide Rally
Fortrea Holdings Inc. saw its stock surge 5.9% to $24.14 on Wednesday, driven by a broad rally that lifted biotechnology stocks across the sector. The move was accompanied by significant gains from several peer companies and positive analyst activity, suggesting growing investor confidence in the biotechnology space. This sector-wide momentum, rather than company-specific news, appears to be the primary factor behind Fortrea's recent advance.
Fortrea Holdings stock hits 52-week high at 23.53 USD By Investing.com
Fortrea Holdings Inc. (FTRE) stock reached a 52-week high of $23.53, reflecting strong investor confidence with a 115% 6-month return and 125.89% 1-year change. Despite missing Q2 2026 earnings expectations, the company improved its full-year guidance, showed stronger cash generation, and enhanced cost control. Analysts like Evercore ISI raised price targets, while UBS initiated coverage with a Neutral rating due to concerns about EBITDA margin expansion and revenue growth.
Fortrea Holdings stock hits 52-week high at 23.53 USD
Fortrea Holdings (FTRE) stock has reached a 52-week high of $23.53, with a 6-month return of 115% and a 1-year change of 125.89%. Despite missing second-quarter earnings expectations, the company improved its full-year guidance, leading Evercore ISI to raise its price target to $25, while UBS initiated coverage with a Neutral rating due to concerns about growth.
Fortrea (NASDAQ:FTRE) Hits New 52-Week High After Analyst Upgrade
Fortrea (NASDAQ:FTRE) shares recently hit a new 52-week high after UBS Group raised its price target to $24.00, though maintaining a neutral rating. The company surpassed quarterly expectations with adjusted EPS of $0.23 and revenue of $678.2 million, leading to a mixed analyst sentiment with a consensus "Hold" rating. Additionally, institutional investors have increased their holdings, while CEO Anshul Thakral sold a portion of his shares for tax obligations.
Fortrea Holdings stock hits 52-week high at 23.53 USD By Investing.com
Fortrea Holdings Inc. stock has reached a new 52-week high of $23.53, reflecting strong investor confidence with a 1-year increase of 125.89%. Despite missing second-quarter earnings expectations, the company improved its full-year guidance, leading Evercore ISI to raise its price target to $25, while UBS initiated coverage with a Neutral rating due to concerns about margin expansion and revenue growth.
9 Health Care Stocks Whale Activity In Today’s Session
This article highlights significant options trading activity, often referred to as "whale activity," involving nine healthcare stocks: Fortrea Holdings (FTRE), Exelixis (EXEL), Danaher Corp (DHR), ImmunityBio Inc (IBRX), The Cigna Group (CI), Edwards Lifesciences Corp (EW), Thermo Fisher Scientific Inc (TMO), Intuitive Surgical Inc (ISRG), and Eli Lilly and Co (LLY). The analysis details specific call and put option trades, their sentiment (bullish, bearish, or neutral), expiration dates, strike prices, and total trade values, indicating potential future price movements for these companies. The information is derived from Benzinga's options activity scanner, which tracks large-sum transactions.
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
Fortrea (Nasdaq: FTRE) has successfully acquired the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million in cash. This acquisition significantly enhances Fortrea's early clinical development capabilities, adding a 200-bed clinical research unit, a 60,000-square-foot bioanalytical laboratory, and expanding its global capacity to over 570 beds. The strategic move aims to integrate clinical pharmacology and bioanalytical functions, streamline study execution, and accelerate drug development for clients.
Fortrea Holdings Inc. (FTRE) Stock forecasts
Morningstar has issued a report on Fortrea Holdings Inc. (FTRE), a global contract research organization, assigning it a "Narrow-Moat" rating. The company is focusing on turnaround efforts to support long-term growth, providing comprehensive clinical trial management and patient access solutions. Fortrea collaborates with various biopharma, medical device, and diagnostic companies.
Fortrea Holdings Inc. (FTRE) Stock Forecasts
This article provides an analyst report from Morningstar on Fortrea Holdings Inc. (FTRE), a global contract research organization. The report focuses on the company's turnaround efforts to support long-term growth and includes details on its current price, fair value, and economic moat. Fortrea specializes in comprehensive clinical trial management and patient access solutions for biopharma, medical device, and diagnostic companies.
Fortrea Holdings Inc. (FTRE) Stock Forecasts
This article is a placeholder from Yahoo Finance for Fortrea Holdings Inc. (FTRE) stock forecasts. However, due to an error, it was unable to retrieve the data, resulting in no actual content being displayed. It primarily consists of navigation, advertisements, and an error message.
Fortrea Holdings Inc. (FTRE) Stock Forecasts
This article provides an Argus research report summary for Fortrea Holdings Inc. (FTRE), a global, late-stage contract research organization. The report offers insights into FTRE's stock, including its current price of $22.75, and details its services in clinical trial management and patient access solutions. Access to the full report requires an upgrade to a premium service.
Fortrea (NASDAQ:FTRE) Stock Rating Lowered by Zacks Research
Zacks Research downgraded Fortrea (NASDAQ:FTRE) from a "hold" to a "strong sell" rating. This comes despite Fortrea exceeding Q2 earnings and revenue expectations, and a broader analyst consensus remaining "hold" with an average price target of $22.10. The company's CEO also recently sold a significant number of shares to cover tax obligations.
Fortrea Holdings (Nasdaq:FTRE) - Stock Analysis
Fortrea Holdings (Nasdaq:FTRE) is a contract research organization trading significantly below its estimated fair value, with earnings projected to grow by 73.47% annually. The company has seen recent positive developments including an acquisition to broaden its early-phase services, key management changes, and an increase in analyst price targets reflecting improved outlooks and financial performance. Despite these positive indicators, it faces minor risks such as share price volatility and being currently unprofitable with limited cash runway.
BofA Securities Maintains Fortrea Holdings(FTRE.US) With Sell Rating, Announces Target Price $15.5
BofA Securities has reiterated its Sell rating on Fortrea Holdings (FTRE.US), setting a target price of $15.5 for the stock. This indicates a negative outlook on the company's future performance by the investment bank.
Fortrea (NASDAQ:FTRE) Upgraded at Wall Street Zen
Wall Street Zen upgraded Fortrea (NASDAQ:FTRE) from "hold" to "buy" after the company exceeded quarterly expectations with an adjusted EPS of $0.23 and revenue of $678.2 million. Despite this upgrade, the broader analyst consensus for Fortrea remains "Hold" with a price target of $22.10. Institutional investors, including Wellington Management and Renaissance Technologies, have also significantly increased their stakes in the company.
Ausbil Investment Management Ltd Decreases Stake in Fortrea Holdings Inc. $FTRE
Ausbil Investment Management Ltd reduced its stake in Fortrea Holdings Inc. by 25.3% in the third quarter, selling 58,122 shares but still retaining 171,704 shares valued at $3.43 million. Despite this, Fortrea reported strong quarterly revenues and adjusted earnings per share that exceeded analyst expectations. The company maintains an average "Hold" rating from analysts with a consensus price target of $22.10.
Fortrea Holdings Price Target Raised to $23.00/Share From $22.00 by Barclays
Barclays has increased its price target for Fortrea Holdings (NASDAQ:FTRE) shares from $22.00 to $23.00. This adjustment follows the firm's reiteration of an "Equal Weight" rating on the stock. The new price target suggests a potential upside of 20.31% from the stock's previous closing price.
Fortrea Holdings Inc stock hits 52-week high at 21.99 USD
Fortrea Holdings Inc. stock reached a new 52-week high of $21.99, currently trading at $22.17, marking a 134% surge over the past six months and a 126.75% increase over the past year. Despite recent Q2 2026 earnings missing Wall Street expectations, analysts like Evercore ISI raised price targets due to healthy bookings and cost control, while UBS initiated coverage with a Neutral rating citing valuation concerns.
Why is Fortrea stock surging today?
Fortrea Holdings Inc. stock surged approximately 8.7% today after Barclays upgraded the contract research organization from Equal-Weight to Overweight, lifting its price target to $23. This upgrade, along with a recent UBS upgrade, improved management stability, an upcoming Q3 earnings release, and a supportive macro environment, contributed to one of the stock's most significant single-session gains recently, pushing it to a new 52-week high.
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
Fortrea (Nasdaq: FTRE) will release its third quarter 2026 financial results on October 29, 2026, before the stock market opens. The company will host a conference call and webcast on the same day at 8:00 a.m. EDT to discuss these results and provide a business update. A replay of the webcast will be available on their investor relations website.
Trading the Move, Not the Narrative: (FTRE) Edition
This article provides an AI-generated analysis for Fortrea Holdings Inc. (NASDAQ: FTRE), indicating a strong overweight bias across all time horizons. It outlines specific trading strategies—Position, Momentum Breakout, and Risk Hedging—with entry zones, targets, and stop losses, and highlights an exceptional 66.0:1 risk-reward short setup. The analysis emphasizes trading the move over the narrative, supported by multi-timeframe signal analysis.
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
Fortrea Holdings Inc. (Nasdaq: FTRE) announced it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The company will host a conference call at 8:00 a.m. ET on the same day to discuss the results, with pre-registration required for participants. A live webcast and replay will be available on Fortrea's investor relations website.
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
Fortrea (Nasdaq: FTRE) will release its third quarter 2026 financial results before market open on Thursday, October 29, 2026. The company will host a conference call at 8:00 a.m. ET on the same day to discuss these results. Participants can pre-register via a provided link for dial-in details or access the live webcast at investors.fortrea.com.
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
Fortrea (Nasdaq: FTRE) announced it will release its third quarter 2026 financial results before market open on Thursday, October 29, 2026. The company will host a conference call at 8:00 a.m. ET to discuss the results, with registration details provided for participants. A live webcast and replay will be available on Fortrea's investor relations website.
UBS Maintains Fortrea Holdings(FTRE.US) With Hold Rating, Maintains Target Price $22
UBS has reiterated its Hold rating for Fortrea Holdings (FTRE.US) and maintained its target price at $22. This indicates that UBS views the stock as fairly valued at its current price.
Fortrea Names Carrie Russell Chief Accounting Officer
Fortrea Holdings Inc. has appointed Carrie Russell as Chief Accounting Officer, formalizing her transition from interim CAO. Her compensation package includes a $340,000 annual base salary and a 40% target bonus, aligning with other senior executives. The company emphasizes that the promotion involved no special arrangements or related-party transactions, reinforcing its commitment to governance.
Fortrea (NASDAQ:FTRE) Stock Rating Upgraded by UBS Group
UBS Group has upgraded Fortrea (NASDAQ:FTRE) to a "hold" rating, aligning with the broader analyst consensus of "Hold" with a $22.00 price target. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Fortrea's CEO also recently sold a significant number of shares to cover tax obligations.
Fortrea Holdings Inc. (NASDAQ:FTRE) Stock Rated "Hold" by Sell-Side Brokerages
Fortrea Holdings Inc. (NASDAQ:FTRE) has received a consensus "Hold" rating from twelve brokerages, with an average 12-month price target of $22.00, compared to its recent opening price of $19.95. The company recently exceeded quarterly earnings expectations, reporting an adjusted EPS of $0.23 against a $0.18 estimate, and revenue of $678.2 million versus $647.6 million expected. Analyst opinions are mixed, and CEO Anshul Thakral sold nearly 100,000 shares to cover tax obligations.
Fortrea Holdings Names Carrie Russell as Chief Accounting Officer, Reveals Compensation Details
Fortrea Holdings Inc. has appointed Carrie Russell as Chief Accounting Officer, effective October 5, 2026. Ms. Russell will receive an annual base salary of $340,000 and an incentive bonus target of 40% of her base salary. She is also eligible for annual long-term incentive awards under the company's 2023 Omnibus Incentive Plan.
Fortrea Holdings Initiated at Neutral by UBS
UBS has initiated coverage on Fortrea Holdings (NASDAQ:FTRE) with a Neutral rating. The firm set a price target of $32. This initiation suggests a cautious outlook on the company's stock by UBS.
UBS initiates Fortrea stock coverage with neutral rating on margin concerns
UBS has initiated coverage on Fortrea (NASDAQ:FTRE) with a Neutral rating and a price target of $22.00, citing concerns over margin expansion and slower revenue growth compared to peers. The firm believes Fortrea is overvalued, noting its lower book-to-bill targets and a lower ranking among CROs in a proprietary survey. Despite recent Q2 2026 earnings misses, Fortrea raised its full-year guidance due to stronger cash generation and cost control, while Evercore ISI also increased its price target to $25 based on positive debt reduction progress.
UBS initiates Fortrea stock coverage with neutral rating on margin concerns
UBS has initiated coverage on Fortrea (NASDAQ:FTRE) with a Neutral rating and a price target of $22.00 due to concerns about the company's EBITDA margin expansion and slower revenue growth compared to peers. The firm believes the market is conservatively pricing in these factors, noting Fortrea's lower book-to-bill targets and a lower ranking in a proprietary CRO survey. Fortrea's stock currently trades at $19.74, and InvestingPro analysis suggests it may be overvalued.
UBS initiates Fortrea stock coverage with neutral rating on margin concerns
UBS has initiated coverage on Fortrea (NASDAQ:FTRE) with a Neutral rating and a $22.00 price target, citing concerns over the company's EBITDA margin expansion and slower revenue growth compared to its peers. The firm believes the market is fairly pricing in conservative growth given structural headwinds, lower booking expectations, and Fortrea's competitive standing based on a proprietary survey. Despite this, InvestingPro analysis suggests Fortrea is currently overvalued, even though the company recently reported a Q2 earnings miss but raised its full-year guidance and has made progress in debt reduction.
Discontinued operations of Fortrea Holdings Inc. – HAN:K67
This article briefly reports on the discontinued operations of Fortrea Holdings Inc. (HAN:K67) on the Hannover Stock Exchange. The status indicates no trades have occurred for this stock.
Inventory turnover of Fortrea Holdings Inc. – HAN:K67
This article from TradingView provides a financial overview of Fortrea Holdings Inc. (HAN:K67) on the Hannover Stock Exchange, focusing on its inventory turnover. It indicates that the market was closed with no trades at the time of publication, and presents the company's financial data.
FOHO5602496 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Fortrea Holdings Inc. 7.5% 01-JUL-2030 bond, identified as FOHO5602496. It covers key facts about the issuer, bond classification, credit risk assessment, interest payment details, and redemption information. The bond has a fixed rate, semi-annual coupon payments, and a face value of $1,000.00 USD.
(FTRE) Movement as an Input in Quant Signal Sets
This article analyzes Fortrea Holdings Inc. (NASDAQ: FTRE) using AI-generated quantitative signals, highlighting weak near-term sentiment but strong mid and long-term outlooks. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis indicating varying support and resistance levels. The report emphasizes an exceptional risk-reward setup targeting a 22.5% gain.
Fortrea Holdings Inc. (FTRE) Stock forecasts
The article indicates that Yahoo Finance experienced an error while retrieving data for Fortrea Holdings Inc. (FTRE) stock forecasts. It also displays general market data for various indices and cryptocurrencies, alongside typical website navigation and advertising elements.
Narrow-Moat Fortrea Focuses on Turnaround Efforts to Support Long-Term Growth
Fortrea, a global late-stage contract research organization, has a long history in pharmaceutical services. The company is currently focused on turnaround efforts and has shown booking strength, which is expected to support a stronger near-term outlook and long-term growth. This analysis provides an overview of Fortrea's business strategy and recent performance.
Fortrea Holdings Inc. (FTRE) Stock Analysis: Navigating a Competitive Biotech Landscape with Strategic Potential
Fortrea Holdings Inc. (FTRE) is a significant player in the biotechnology sector, providing development solutions for biopharmaceutical products. Despite a robust stock recovery and investor confidence, indicated by its forward P/E, the company faces challenges with negative revenue growth and profitability. Analysts offer a mixed outlook, with the stock positioned as a watchful hold for investors who believe in its long-term strategic initiatives within the dynamic biotech industry.
Fortrea Holdings (FTRE) grants its CFO 144,434 stock units vesting over three years
Fortrea Holdings Inc. (FTRE) has granted its Chief Financial Officer, Jason Fredrick Knoblauch, 144,434 Restricted Stock Units (RSUs). These RSUs, representing one share of Fortrea common stock each, will vest in three equal annual installments beginning September 10, 2027. This grant was reported in a Form 4 filing with the SEC and signifies a neutral impact on the company's sentiment.
Fortrea Holdings Inc. $FTRE Shares Sold by Engineers Gate Manager LP
Engineers Gate Manager LP significantly reduced its stake in Fortrea Holdings Inc. by 49.5% in the second quarter, selling over 115,000 shares. Despite this, Fortrea exceeded its quarterly earnings and revenue expectations, reporting $0.23 EPS against an estimated $0.18 and revenue of $678.2 million. Analyst sentiment for FTRE remains mixed, with an average "Hold" rating and a consensus price target of $22, although some firms have issued "Buy" ratings and higher price targets.
Fortrea (NASDAQ:FTRE) Shares Up 3.6% - Here's Why
Fortrea (NASDAQ:FTRE) shares rose 3.6% in mid-day trading due to the company exceeding quarterly expectations with $0.23 EPS against an estimated $0.18, and revenue of $678.2 million versus $647.6 million. Despite a significant drop in trading volume, analyst sentiment remains mixed but generally positive, with a consensus "Hold" rating and an average price target of $22.00. The article also details recent analyst ratings, insider selling, and institutional investor activity.
Former Fortrea (FTRE) officer plans stock sale partly to cover taxes
Former Fortrea officer Jill G. Mcconnell has filed a Rule 144 notice to sell 1,051 shares of Fortrea Holdings Inc. common stock, valued at approximately $17,705.57. Part of this sale is intended to cover tax obligations from vested equity awards. The filing also notes a previous sale of 4,892 shares on August 19, 2026, for about $88,975.21.
Fortrea (FTRE) COO sells shares in mandatory tax trade
Fortrea's COO, Mark A. Morais, executed a mandatory "sell to cover" transaction, selling 3,149 shares of Common Stock at a weighted average price of $16.85 per share to satisfy tax withholding obligations following the vesting of 7,157 Restricted Stock Units. This transaction was not a discretionary trade. After the sale, Morais directly held 83,525 RSUs and 81,794 shares of Common Stock, with an additional 4,625 shares held indirectly through his spouse.
Fortrea to Participate in September Investor Conferences
Fortrea Holdings Inc. (Nasdaq: FTRE) announced that its CEO, CFO, and SVP of Investor Relations will participate in three investor conferences in September 2026: the Baird Global Healthcare Conference, the Deutsche Bank Healthcare Summit, and the RBC Pharma Services and Life Science Tools Virtual Conference. The company will engage in fireside chats, as well as one-on-one and group meetings to discuss its clinical development solutions. A live webcast and replay of the Baird fireside chat will be available on Fortrea's Investor Relations website.
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fortrea Holdings Inc. announced the grant of inducement awards, consisting of restricted stock units (RSUs) and performance share units (PSUs), to five newly hired employees on September 10, 2026. These awards include significant grants to Jason Knoblauch, the new Chief Financial Officer, and are designed to incentivize new employees under Nasdaq Listing Rule 5635(c)(4). The grants are subject to continuous employment and performance goals, with vesting periods typically spanning three years.
Tax-related Fortrea (FTRE) stock sale adds to ex-officer’s recent trades
An amended Rule 144 notice reveals that former Fortrea Holdings Inc. officer Jill G. Mcconnell plans to sell 1,032 shares of FTRE common stock to cover a tax obligation from a vested equity award. This planned sale follows several prior sales by Mcconnell in the past three months, totaling thousands of shares. The amendment also corrected the Date of Notice to September 11, 2026.
